Universal Beteiligungs und Servicegesellschaft mbH Purchases New Shares in Revolution Medicines, Inc. (NASDAQ:RVMD)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH made a significant investment of $2.34 million in Revolution Medicines, Inc., acquiring 66,251 shares of the company's stock.
• Revolution Medicines reported a loss of $1.13 EPS for the last quarter, slightly missing analysts' consensus estimates, with expectations of a -3.49 EPS for the current fiscal year.
• Despite recent losses, eleven analysts have rated Revolution Medicines with a "buy," with an average target price of approximately $68.91.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 66,251 shares of the company's stock, valued at approximately $2,343,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Prudential Financial Inc. lifted its position in Revolution Medicines by 11.0% during the fourth quarter. Prudential Financial Inc. now owns 46,859 shares of the company's stock valued at $2,050,000 after purchasing an additional 4,645 shares during the last quarter. Norges Bank bought a new stake in shares of Revolution Medicines during the 4th quarter worth $76,197,000. California Public Employees Retirement System grew its position in Revolution Medicines by 17.3% in the fourth quarter. California Public Employees Retirement System now owns 268,289 shares of the company's stock worth $11,735,000 after acquiring an additional 39,475 shares in the last quarter. B. Metzler seel. Sohn & Co. AG bought a new position in Revolution Medicines in the fourth quarter valued at $752,000. Finally, Geode Capital Management LLC raised its position in Revolution Medicines by 12.7% during the fourth quarter. Geode Capital Management LLC now owns 4,086,199 shares of the company's stock valued at $180,171,000 after purchasing an additional 459,174 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company's stock.

Revolution Medicines Stock Down 1.7%

Shares of Revolution Medicines stock traded down $0.64 during trading on Friday, reaching $36.63. 978,549 shares of the stock were exchanged, compared to its average volume of 1,474,059. Revolution Medicines, Inc. has a 1 year low of $29.17 and a 1 year high of $62.40. The firm has a market cap of $6.82 billion, a price-to-earnings ratio of -9.16 and a beta of 1.16. The stock's fifty day moving average is $38.71 and its 200 day moving average is $38.92.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same period last year, the firm posted ($0.70) earnings per share. Equities analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on RVMD shares. The Goldman Sachs Group started coverage on Revolution Medicines in a research report on Tuesday, July 15th. They set a "buy" rating and a $65.00 price objective on the stock. Wedbush restated an "outperform" rating and issued a $73.00 price objective (up from $67.00) on shares of Revolution Medicines in a report on Tuesday, June 24th. Needham & Company LLC reaffirmed a "buy" rating and issued a $57.00 price objective on shares of Revolution Medicines in a research note on Tuesday, June 24th. Guggenheim reiterated a "buy" rating and issued a $80.00 target price on shares of Revolution Medicines in a research report on Wednesday, June 25th. Finally, HC Wainwright restated a "buy" rating and set a $72.00 price target (down from $73.00) on shares of Revolution Medicines in a research report on Wednesday, May 14th. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $68.91.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.